Pulmonary Vasculature Latest News Archive
Pulmonary hypertension was confirmed by invasive methods in 68% and 47% of patients with and without a measurable tricuspid regurgitation velocity, respectively.
Increased pulmonary pressures, right ventricular dysfunction, and a stiffer pulmonary vascular bed were typical characteristics of early pulmonary vascular disease onset in young adults who were born preterm.
There were no significant differences in pulmonary arterial hypertension survival based on therapy type, age was an important modifier.
Pulmonary arterial stiffness was related to mean pulmonary arterial pressure and heart rate in patients with untreated idiopathic pulmonary arterial hypertension.
The Pediatric Index Pulmonary Hypertension Intensive Care Mortality model was compared with the Pediatric Risk of Mortality 2 and 3 models to determine the best model for predicting mortality.
The fractal dimension of right ventricular trabecular complexity was a good reproducible marker of remodeling in pulmonary hypertension.
Right ventricular base/apex ratio reference values may help clinicians diagnose children with pulmonary arterial hypertension.
Many healthcare providers reported that they often do not have the time to counsel their patients with pulmonary arterial hypertension on pregnancy risks.
Management strategies were discussed for subtypes of PAH-congenital heart disease including Eisenmenger syndrome, PAH with persistent systemic to pulmonary shunts, and PAH with small or coincidental defect or PAH after defect closure.
After iron supplementation, patients with cyanosis experienced significant improvements in hemoglobin concentration, hematocrit, mean corpuscular volume, ferritin, and transferrin saturation
There was no significant difference in efficacy between sildenafil and bosentan initial combination therapy and sildenafil monotherapy in patients with systemic sclerosis-related pulmonary arterial hypertension.
Precapillary pulmonary hypertension and obstructive sleep apnea may be causative factors for central sleep apnea and pulmonary hypertension, respectively.
Arrhythmia was a significant predictor of mortality in adult patients with congenital heart disease and pulmonary arterial hypertension.
The variables for the stepwise echocardiographic score included right ventricular systolic pressure, early pulmonary regurgitation gradient, right atrial area size, tricuspid regurgitation velocity, left ventricle eccentricity index, and right ventricle fractional area change.
There was a significant relationship between brain natriuretic peptide levels and mortality in patients with group 1 pulmonary arterial hypertension.
The 1-year survival rate after lung transplantation in patients with a mean pulmonary arterial pressure ≥25 mm Hg was lower than the survival rate of those with a mean pulmonary arterial pressure <25 mm Hg.
A single-beat estimation of preload recruitable stroke work and its coupling with pulmonary arterial load in pulmonary arterial hypertension provided high accuracy for evaluating right ventricular contractility.
Men with higher estradiol and estradiol/testosterone levels had an increased risk for pulmonary arterial hypertension.
Serum chloride was a strong and independent predictor of mortality at 6 months after a pulmonary arterial hypertension diagnosis.
The "egg-and-banana" sign is a valid computed tomography marker of pulmonary hypertension.
At the end of 6 months, the rate of VTE recurrence was 4% among rivaroxaban patients vs 11% in the dalteparin arm (hazard ratio [HR] 0.43, 95% CI: 0.19 to 0.99).
A protocolized study including initiation of VA-ECMO may reduce mortality in patients with massive PE.
Ischemic heart disease and kidney dysfunction were identified as 2 comorbidities that may affect outcomes in idiopathic pulmonary arterial hypertension.
Stem cell therapy targeting right ventricular failure may help improve pulmonary circulation in pulmonary arterial hypertension.
The sNDA is accompanied by results from the MERIT-1 trial, a Phase 2 randomized, placebo-controlled, double-blind study which assessed the efficacy, safety and tolerability of macitentan 10mg in 80 patients with inoperable CTEPH.
Walking a distance of >400 meters in the 6-minute walk test was associated with a reduced risk for pulmonary arterial hypertension-related death or hospitalization.
In patients with pulmonary arterial hypertension or distal chronic thromboembolic pulmonary hypertension, targeted pharmacologic treatment was associated with an increase in achieved therapeutic goals.
Increased right atrial and pulmonary wedge pressures and increased thyroid disease prevalence were associated with atrial arrhythmia development in idiopathic or systemic sclerosis-related pulmonary arterial hypertension.
Prescribers tend to favor a frequency of 3 times per day for oral treprostinil dosing in patients with pulmonary arterial hypertension.
N-terminal-pro brain natriuretic peptide may be a useful biomarker for both mortality and respiratory exacerbations in pediatric patients with pulmonary hypertension.
Patients with pulmonary hypertension have a high risk for adverse events during and following cardiac catheterization, but high case volume may help ameliorate this risk.
Nearly two-thirds of phosphodiesterase-5 inhibitor prescriptions are inconsistent with pulmonary hypertension guidelines.
Patients with pulmonary arterial hypertension may be better identified with the use of a claims-based algorithm that includes ICD-9-CM codes, electronic medical records, and more.
Right atrium enlargement may predict the risk for supraventricular arrhythmias in patients with pulmonary arterial hypertension.
Women with pulmonary arterial hypertension may have better long-term prognoses compared with men, potentially because of improvements in right ventricular function.
A 3-month risk for a thromboembolic event was assessed using a pulmonary embolism rule-out criteria strategy and compared with a conventional strategy in patients with a low clinical probability of pulmonary embolism.
Acute pulmonary embolism may be managed in an outpatient setting when the patient has a low risk for mortality.
Hypoxemia is associated with reduced survival in patients with idiopathic or heritable pulmonary arterial hypertension.
Peak circulatory may provide reliable prognostic information in patients with idiopathic pulmonary arterial hypertension.
The 6MWT is a clinically relevant and appropriate target for patients with pulmonary arterial hypertension.
Certain risk scores may not be reliable for predicting the presence of a pulmonary embolism in pregnant or postpartum women.
Several drugs may demonstrate different safety profiles and side effects that warrant a change in treatment for individuals with pulmonary hypertension.
To minimize the "learning effect" and improve accuracy, patients with suspected pulmonary hypertension should undergo two 6-minute walk tests.
Monitoring the plasma BNP level in individuals with pulmonary arterial hypertension may aid clinicians in therapeutic decision-making and overall prediction of 5-year survival rate.
Researchers discovered an association between global pulmonary vascular remodeling and pulmonary hypertension in patients with heart failure.
In a postmarketing surveillance study, ambrisentan demonstrated tolerability and potential effectiveness for pulmonary arterial hypertension treatment.
Patients diagnosed with an intermediate-risk pulmonary embolism may be able to start oral anticoagulation therapy after completing 72 hours of heparin therapy during hospitalization.
A pilot study will assess the effectiveness of milrinone in a small group of infants born with congenital diaphragmatic hernia.
Compared with age, pulmonary hypertension, right ventricular failure, and cardiopulmonary bypass time may better predict outcomes in heart transplantation.
Treprostinil, a prostacyclin derivative, used in an implantable delivery system may be an effective treatment alternative for pulmonary arterial hypertension.
Researchers examined the effect of riociguat compared with placebo on the REVEAL risk score and long-term outcomes for pulmonary arterial hypertension.
Smoke-free ordinances may reduce the number of lung cancer cases.
A decrease in baseline estimated glomerular filtration rate in PAH may be a predictor of hospitalization and mortality.
Catheter-directed thrombolysis vs systemic thrombolysis strategies show different risk outcomes for patients with intermediate-risk pulmonary embolism.
Several clinical predictors of pediatric pulmonary embolism have been identified.
Use of riociguat may be considered for severe pulmonary arterial hypertension in pediatric patients.
Balloon pulmonary angioplasty may improve hemodynamics in patients with CTEPH.
Patients with pulmonary arterial hypertension may have an impaired cerebral pressure-flow relationship.
Switching from a phosphodiesterase type 5 inhibitor to riociguat significantly improves pulmonary arterial compliance in patients with PAH.
Pulmonary artery compliance may be an independent predictor of survival and prognosis in patients with pulmonary artery hypertension associated with congenital heart disease.
Nebulized glycopyrrolate improves lung function and patient-reported outcomes in patients with moderate to very severe COPD.
Pulmonary arterial hypertension associated with the use of methamphetamine is a severe, progressive form of the disease.
Patients with hereditary hemorrhagic telangiectasia may develop pulmonary hypertension.
Patients with chronic thromboembolic pulmonary hypertension may have higher rates of depression compared to patients with PAH.
Having at least 2 features of pulmonary veno-occlusive disease is linked to reduced survival rate in patients with SSc and PAH.
Right ventricular base/apex ratio during systole can discriminate between types of pulmonary hypertension.
Quality of life in patients with idiopathic pulmonary fibrosis can be significantly affected by depression and anxiety.
Patients with saddle and nonsaddle pulmonary embolism have similar short-term outcomes, despite more serious symptoms being present in saddle pulmonary embolism.
The European Society of Cardiology and the European Society for Vascular Surgery have developed new guidelines on the diagnosis and treatment of peripheral arterial disease.
Patients with high-risk obstructive sleep apnea are almost 4 times more likely to have postoperative complications vs patients with low-risk obstructive sleep apnea.
Pulmonary endarterectomy is an effective treatment for patients with chronic thromboembolic pulmonary hypertension.
People with obstructive sleep apnea could have a higher risk for hypercoagulability.
Bosentan has been approved for use in pediatric pulmonary arterial hypertension in children aged 3 years or older.
Selexipag Associated With Reduced Morbidity, Mortality Risk in Connective Tissue Disease-Associated PAH
In patients with connective tissue disease-associated pulmonary arterial hypertension, selexipag may reduce risk for morbidity and mortality.
Anti-U1 ribonucleoprotein antibodies may increase chances of survival in patients with pulmonary arterial hypertension as a complication of systemic lupus erythematosus.
Opioid use increases cardiac event risk in older adults with chronic obstructive pulmonary disease.
Pulmonary artery to aorta ratio measurement can effectively predict survival in patients with idiopathic pulmonary fibrosis.
Multiple factors have influenced a 6-minute reduction in sarcoidosis-associated pulmonary hypertension.
Mean arterial pressure in patients with peripheral artery disease decreased as a result of antihypertensive medication.
Mortality rates in SLE-associated pulmonary arterial hypertension are higher compared to the general SLE population even-though diagnostic and treatment strategy have improved in the last 50 years.
Restrictive spirometry pattern and reduced forced vital capacity (FVC) are associated with a higher risk for arterial stiffness regardless of sex.
Researchers examined statin therapy as a method of risk reduction in lower extremity amputation.
A case study of a patient presented to the emergency room for right upper extremity deep vein thrombosis after rib resection and subclavian vein stent placement 15 years ago.
An increased risk of sepsis, venous thromboembolism and fracture was linked to short term use of oral corticosteroids.
Combination therapy with an inhaled long-acting beta2-agonist and an inhaled corticosteroid did not affect all-cause mortality compared with inhaled placebo.
Results from the EINSTEIN CHOICE trial plus an interview with investigator Philip Stephen Wells, MD, FRCP(C), MSc.
Survival rates were high for patients with both central and peripheral pulmonary emboli.
While data are conflicting, statin use in COPD may help reduce pulmonary-related and all-cause mortality.
After intracerebral hemorrhage, both acute renal failure and deep venous thrombosis have increased.
Pulmonary embolism risk after cerebral venous thromboembolism is significantly lower than after deep vein thromboembolism.
Patients with giant cell arteritis were more likely to experience venous thromboembolism during the first 3 months following diagnosis.
Initial combination therapy with ambrisentan and tadalafil reduced the risk for first clinical failure event in patients with connective tissue disease-associated pulmonary arterial hypertension.
Patients with resistant hypertension had a modest increase in risk of developing sleep apnea compared to those with nonresistant hypertension.
New Metabolites Associated With Hemodynamic Indicators of Right Ventricular-Pulmonary Vascular Dysfunction Discovered
Researchers discovered 21 new metabolites associated with 2 or more hemodynamic indicators of right ventricular-pulmonary vascular function.
RIETE registry reveals an association between improved hospital care and reduced pulmonary embolism mortality.
Dabigatran now approved for prohylaxis of deep vein thrombosis and pulmonary embolism in patients who have undergone hip replacement surgery.
Before inserting peripherally placed central catheters (PICCs), physicians should weigh potential risks for each patient with the ultimate clinical benefit.
Prolonged television watchers have an increased risk of pulmonary embolism mortality.
Researchers analyze the efficacy and safety of exercise training in pulmonary hypertension.
The Cardiology Advisor Articles
- Does Pre-Existing PH Affect Outcomes in Transcatheter Mitral Valve Repair?
- How Has the Medicaid Expansion Affected Patients Hospitalized With Acute MI?
- Macitentan Not Superior to Placebo for Improving Exercise Capacity in Eisenmenger Syndrome
- Occupational Metal, Pesticide Exposure May Be Associated With Increased CVD Risk
- FDA to Review Tafamidis for Treatment of Transthyretin Amyloid Cardiomyopathy
- ASH Develops Practice Guidelines for Venous Thromboembolism
- Tetralogy of Fallot: Long-Term Outcomes After Surgical Repair
- Stethoscopes in ICU Show High Levels of Bacterial Contamination
- Catheter Ablation Superior to Drug Therapy for Atrial Fibrillation in Heart Failure
- Trends in Endocarditis Incidence After Implementation of 2007 AHA Recommendations
- Researchers Identify Golden Ratio Between Pulmonary Pressure Components in PAH
- FDA: Potential Increased Mortality With Paclitaxel-Coated Balloons, Stents for PAD
- Inhaled Dry Powder Formulation of Treprostinil Well Tolerated in PAH
- Elevated Myocardial T1 Associated With Increased Septal Angle in PAH
- Pulmonary Hypertension Intensive Care Options Depend on Treatment Goals